Discover
REGN
Regeneron Pharmaceuticals, Inc.
624.72
1 x 634.89
1 x 626.19
bid
ask
+
1.18
0.19%
1 @ 06:15 AM
624.72 +0.00 (0.00%)
| Ytd | -19.06% | |
| 1y | 14.05% |
623.89
day range
632.85
529.69
52 week range
821.11
| Open | 629.48 | Prev Close | 623.54 | Low | 623.89 | High | 632.85 | Mkt Cap | 65.50B |
| Vol | 987.29K | Avg Vol | 991.83K | EPS | 40.98 | P/E | 15.24 | Forward P/E | 11.62 |
| Beta | 0.24 | Short Ratio | 2.72 | Inst. Own | 92.23% | Dividend | 3.76 | Div Yield | 0.60 |
| Ex Div Date | 05-20 | Earning | 07-30 | 50-d Avg | 659.41 | 200-d Avg | 699.49 | 1yr Est | 833.31 |
| Income Statement | |||
| Total Revenue | 3.61B | ||
| Revenues (USD) | 3.61B | ||
| Cost of Revenue | 669.40M | ||
| Gross Profit | 2.94B | ||
| Operating Expenses | 2.29B | ||
| Research and Development Expense | 1.54B | ||
| Selling, General and Administrative Expense | 647.70M | ||
| Operating Income | 642.90M | ||
| Interest Expense | 12.90M | ||
| Income Tax Expense | 104.00M | ||
| Net Income | 727.20M | ||
| Net Income Common Stock | 727.20M | ||
| Net Income Common Stock (USD) | 727.20M | ||
| Consolidated Income | 727.20M | ||
| Earnings per Basic Share | 6.99 | ||
| Earnings per Basic Share (USD) | 6.99 | ||
| Earnings per Diluted Share | 6.75 | ||
| Dividends per Basic Common Share | 0.94 | ||
| Earning Before Interest & Taxes (EBIT) | 844.10M | ||
| Earning Before Interest & Taxes (USD) | 844.10M | ||
| Weighted Average Shares | 104.00M | ||
| Weighted Average Shares Diluted | 107.70M | ||
| Balance Sheet | |||
| Cash and Equivalents | 2.96B | ||
| Cash and Equivalents (USD) | 2.96B | ||
| Investments | 15.58B | ||
| Investments Current | 5.79B | ||
| Investments Non-Current | 9.79B | ||
| Trade and Non-Trade Receivables | 5.73B | ||
| Current Assets | 18.21B | ||
| Property, Plant & Equipment Net | 5.27B | ||
| Total Assets | 40.87B | ||
| Debt Current | 720.00M | ||
| Total Debt | 2.71B | ||
| Current Liabilities | 5.11B | ||
| Debt Non-Current | 1.99B | ||
| Total Liabilities | 9.45B | ||
| Accumulated Retained Earnings (Deficit) | 36.42B | ||
| Accumulated Other Comprehensive Income | 11.90M | ||
| Shareholders Equity | 31.42B | ||
| Shareholders Equity (USD) | 31.42B | ||
| Assets Non-Current | 22.66B | ||
| Total Debt (USD) | 2.71B | ||
| Deferred Revenue | 861.30M | ||
| Goodwill and Intangible Assets | 1.29B | ||
| Inventory | 3.10B | ||
| Liabilities Non-Current | 4.34B | ||
| Trade and Non-Trade Payables | 1.03B | ||
| Tax Assets | 4.19B | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 123.20M | ||
| Net Cash Flow from Financing | -802.20M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -153.10M | ||
| Capital Expenditure | -230.60M | ||
| Issuance (Purchase) of Equity Shares | -704.40M | ||
| Payment of Dividends & Other Cash Distributions | -97.80M | ||
| Net Cash Flow from Investing | -428.90M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -149.40M | ||
| Net Cash Flow from Operations | 1.08B | ||
| Effect of Exchange Rate Changes on Cash | -900.00K | ||
| Share Based Compensation | 257.40M | ||